this company is absurdly undervalued and have numerous drugs in the pipeline. Strong management and building this the way it should be. It is clear they are putting strategies together to deal with the success they are about to achieve
The stock is just finally getting noticed. Been under the radar for awhile but their drug candidates both have blockbuster potential licensed from Ligand (largest investor in VKTX) which is very successful biotech firm that has quite a FDA approved drugs. VKTX ipo's at $8 per share in 2015.